Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström's macroglobulinemia.

Meletios A Dimopoulos1, Athanasios Anagnostopoulos

  • 1Department of Clinical Therapeutics, University of Athens School of Medicine, 227 Kifissias Avenue, 14561 Kifissia, Athens, Greece. mdimop@med.uoa.gr

Best Practice & Research. Clinical Haematology
|July 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.

Annals of hematology·2020
Same author

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

The Lancet. Haematology·2020
Same author

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.

Leukemia·2020
Same author

Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.

Annals of hematology·2020
Same author

Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.

Clinical lymphoma, myeloma & leukemia·2020
Same author

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.

Blood cancer journal·2020
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Waldenström's macroglobulinemia (WM) diagnosis requires bone marrow infiltration and IgM monoclonal protein. Treatment options include chemotherapy, nucleoside analogues, rituximab, and stem-cell transplantation, with survival depending on prognostic factors.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström's macroglobulinemia (WM) is characterized by bone marrow infiltration of lymphoplasmacytoid lymphoma and serum IgM monoclonal protein.
  • The malignant cells in WM are thought to originate from postgerminal-center B cells.
  • Clinical symptoms and lab findings in WM result from tumor infiltration and IgM properties.

Purpose of the Study:

  • To outline the diagnostic criteria for Waldenström's macroglobulinemia.
  • To describe the clinical manifestations and laboratory abnormalities associated with WM.
  • To review current treatment strategies and prognostic factors for WM patients.

Main Methods:

  • Diagnostic criteria involve bone marrow biopsy and serum protein electrophoresis.

Related Experiment Videos

  • Treatment approaches discussed include chemotherapy (chlorambucil), nucleoside analogues (fludarabine, cladribine), and monoclonal antibody therapy (rituximab).
  • High-dose therapy with autologous stem-cell transplantation is considered for advanced or resistant disease.

    • Main Results:

    • Asymptomatic WM patients require monitoring without immediate treatment.
    • Frontline treatment choices for symptomatic WM include chlorambucil, fludarabine/cladribine, and rituximab.
    • High-dose therapy with autologous stem-cell transplantation shows efficacy in advanced/resistant WM.
    • Patient age, hemoglobin levels, and pre-treatment serum beta2-microglobulin are key prognostic indicators.

    Conclusions:

    • WM diagnosis is based on specific hematologic and immunologic findings.
    • Treatment decisions for WM are guided by disease status and patient characteristics.
    • Prognostic variables are crucial for predicting survival outcomes in Waldenström's macroglobulinemia.